Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lanabecestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 known ✓ | P56817 | 18/20 | 1.00 |
| ▸ | APP | P05067 | 16/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanabecestat SCHEMBL9948518 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL9947926 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL18562845 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL10249926 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL29358506 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL9948271 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL23085139 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL9947974 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL9947972 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 | |
| Lanabecestat SCHEMBL20702043 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175749-A1 | LANABECESTAT FOR WEIGHT LOSS | ASTRAZENECA AB (SE) | 2022-06-09 | — | — | US | claimed |
| US-10548882-B2 | Camsylate salt | ASTRAZENECA AB (SE) | 2020-02-04 | — | — | US | claimed |
| US-20190038613-A1 | COMBINATION THERAPY | LILLY CO ELI (US) | 2019-02-07 | — | — | US | claimed |
| EP-2655378-B1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-03-01 | — | — | EP | claimed |
| EP-2864316-B1 | Camsylate salt of (1r,1'R,4R)- 4-methoxy-5\"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'H-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4\"-amine and crystalline forms thereof for the treatment of A[beta]-related pathologies such as e.g. Alzheimer's disease | ASTRAZENECA AB (SE) | 2016-12-14 | — | — | EP | claimed |
| EP-3064494-A1 | A PROCESS FOR THE PREPARATION OF A CAMSYLATE SALT ((1S)-(+)-10 CAMPHORSULFONIC ACID) OF (1R,1'R,4R)- 4-METHOXY-5\"-METHYL-6'-[5-(PROP-1-YN-1-YL)PYRIDIN- 3-YL]-3'H-DISPIRO[CYCLOHEXANE-1,2'-INDEN-1'2'-IMIDAZOLE]-4\"-AMINE | AstraZeneca AB (SE) | 2016-09-07 | — | — | EP | claimed |
| US-20160184303-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-06-30 | — | — | US | claimed |
| US-9248129-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | claimed |
| US-20150133471-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | US | claimed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | claimed |
| US-20220175749-A1 | LANABECESTAT FOR WEIGHT LOSS | ASTRAZENECA AB (SE) | 2022-06-09 | — | — | US | disclosed |
| US-20220175749-A1 | LANABECESTAT FOR WEIGHT LOSS | ASTRAZENECA AB (SE) | 2022-06-09 | — | — | US | disclosed |
| US-20220175749-A1 | LANABECESTAT FOR WEIGHT LOSS | ASTRAZENECA AB (SE) | 2022-06-09 | — | — | US | disclosed |
| US-10548882-B2 | Camsylate salt | ASTRAZENECA AB (SE) | 2020-02-04 | — | — | US | disclosed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133471-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CTSD 50/4885 |
| US-10548882-B2 | Camsylate salt | PSEN1, PSEN2, MAPT | BACE1 8/4885APP 6/4885CTSD 1439/4885 |
| US-20190038613-A1 | COMBINATION THERAPY | PSEN1, PSEN2, CHRNA4 | BACE1 4/4885APP 16/4885CTSD 3462/4885 |
| US-20220175749-A1 | LANABECESTAT FOR WEIGHT LOSS | GIPR, GLP1R, IGF1R | BACE1 1515/4885APP 4212/4885CTSD 4501/4885 |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CTSD 50/4885 |
| US-20160184303-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CTSD 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.